Trial Profile
A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Sorafenib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms TIES
- 05 Jun 2010 Results of a multivariate analysis investigating the effects of imbalances in prognostic factors between the study arms on the primary endpoint were presented at ASCO 2010.
- 21 May 2010 Results will be presented at the 2010 ASCO Annual Meeting, according to an Onyx Pharmaceuticals media release.
- 22 Jul 2009 Primary endpoint 'Progression free survival' has been met, according to an Onyx Pharmaceuticals media release.